abstract |
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. In addition, specific irreversible inhibitors of the menin-MLL interaction have been described. Also disclosed are pharmaceutical compositions comprising such compounds. A menin-MLL irreversible inhibitor alone or in another for the treatment of an autoimmune disease or condition, a heteroimmune disease or condition, cancer such as lymphoma, leukemia and other diseases or conditions dependent on the menin-MLL interaction. Methods for use with therapeutic agents are disclosed. |